
LeonaBio Inc (LONA) Stock Forecast & Price Target
LeonaBio Inc (LONA) Analyst Ratings
Bulls say
LeonaBio is a clinical-stage biopharmaceutical company with a pipeline of promising drug candidates, including lasofoxifene and ATH-1105, that have the potential to address high unmet medical needs in metastatic breast cancer and ALS. The company's development strategy, including a focus on combination therapies and label expansions, positions it well for success in the competitive oncology market. Additionally, LeonaBio's successful Phase 2 trials and well-funded financials make it an attractive investment opportunity.
Bears say
LeonaBio is currently developing lasofoxifene, a potential treatment for ER+/HER2- metastatic breast cancer (mBC) with potentially differentiated benefits compared to existing standard of care (SOC). However, despite the promising clinical profile and potential best-in-class efficacy, the company may face challenges in penetrating the competitive HER2- mBC market and may also have to navigate potential drug-drug interactions due to its mechanism of action as a selective estrogen receptor modulator (SERM). Additionally, while early data does support the safety and efficacy of lasofoxifene, more data and regulatory approvals are needed before it can be considered a commercially viable therapy.
This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.
LeonaBio Inc (LONA) Analyst Forecast & Price Prediction
Start investing in LeonaBio Inc (LONA)
Order type
Buy in
Order amount
Est. shares
0 shares